Zaltrap

Chemical Nameziv-aflibercept
Dosage FormInjection (intravenous; 100 mg/4 mL (25 mg/mL), 200 mg/8 mL (25 mg/mL))
Drug ClassInhibitors
SystemDigestive
CompanyRegeneron Pharmaceuticals Inc.
Approval Year2012

Indication

  • Indicated for use in combination with Folfiri for the treatment of metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin regimen.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zaltrap (ziv-aflibercept) Prescribing Information 2012Sanofi-aventis U.S. LLC, Bridgewater, NJ